Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior

UCB, a global biopharmaceutical company, today announced that the final analysis of an open-label extension (OLE) study with ...